Cite
CD30 expression defines a novel subgroup of diffuse large B-cell lymphoma with favorable prognosis and distinct gene expression signature: a report from the International DLBCL Rituximab-CHOP Consortium Program Study.
MLA
Shimin Hu, et al. “CD30 Expression Defines a Novel Subgroup of Diffuse Large B-Cell Lymphoma with Favorable Prognosis and Distinct Gene Expression Signature: A Report from the International DLBCL Rituximab-CHOP Consortium Program Study.” Blood, vol. 121, no. 14, Apr. 2013, pp. 2715–24. EBSCOhost, https://doi.org/10.1182/blood-2012-10-461848.
APA
Shimin Hu, Xu-Monette, Z. Y., Balasubramanyam, A., Manyam, G. C., Visco, C., Tzankov, A., Wei-min Liu, Miranda, R. N., Li Zhang, Montes-Moreno, S., Dybkær, K., Chiu, A., Orazi, A., Youli Zu, Bhagat, G., Richards, K. L., Hsi, E. D., Choi, W. W. L., van Krieken, J. H., & Qin Huang. (2013). CD30 expression defines a novel subgroup of diffuse large B-cell lymphoma with favorable prognosis and distinct gene expression signature: a report from the International DLBCL Rituximab-CHOP Consortium Program Study. Blood, 121(14), 2715–2724. https://doi.org/10.1182/blood-2012-10-461848
Chicago
Shimin Hu, Zijun Y. Xu-Monette, Aarthi Balasubramanyam, Ganiraju C. Manyam, Carlo Visco, Alexander Tzankov, Wei-min Liu, et al. 2013. “CD30 Expression Defines a Novel Subgroup of Diffuse Large B-Cell Lymphoma with Favorable Prognosis and Distinct Gene Expression Signature: A Report from the International DLBCL Rituximab-CHOP Consortium Program Study.” Blood 121 (14): 2715–24. doi:10.1182/blood-2012-10-461848.